Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations, 51273-51275 [2010-20572]
Download as PDF
<![CDATA[
51273
Federal Register / Vol. 75, No. 160 / Thursday, August 19, 2010 / Notices
A.12–1—ESTIMATES OF NET HOUR BURDEN REDUCTION
Type of
respondents
Number of
respondents
Stage 1: Immediate .........................................................................
Stage 1: Expected Reduction in Current burden (assuming 100
universities and at median) ..........................................................
Net reduction in burden ...................................................................
Stage 1: Future ................................................................................
Stage 2: Expected Reduction in Current burden (assuming 100
universities and at median) ..........................................................
Net reduction in burden ...................................................................
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT:
To
emcdonald on DSK2BSOYB1PROD with NOTICES
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Stefano
Bertuzzi, Health Science Policy Analyst,
Office of Science and Technology
Policy, OSP, OD; NIH, Building 1, Room
218, 9000 Rockville Pike, Bethesda, MD
20892 or call non-toll-free number 301–
495–9286 or e-mail your request,
including your address to:
stefano.bertuzzi@nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: August 12, 2010.
Lynn D. Hudson,
Director, Office of Science Policy Analysis,
National Institutes of Health.
1
72
+7,200
100
100
100
4
4
4
40
............................
1.0
¥16,000
¥8,800
+400
100
100
4
4
40
............................
¥16,000
¥15,600
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day-10–0798]
Proposed Data Collections Submitted
for Public Comment and
Recommendations; Correction
Centers for Disease Control and
Prevention
Notice; Correction
The Centers for Disease Control and
Prevention published a document in the
Federal Register titled 60-day 10–0798.
The document contained the incorrect
OMB number and expiration date.
FOR FURTHER INFORMATION CONTACT:
Maryam Daneshvar, 404–639–4604
Correction
In the Federal Register of August 12,
2010, Volume 75, Number 155, in FR
Doc. 2010–19911 page 48972, under the
Proposed Project paragraph correct
(OMB No. 0920–0753 exp. 10/31/2010)
to read: (OMB No. 0920–0798 exp. 1/31/
2011).
Dated: August 12, 2010.
Maryam I, Daneshvar,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2010–20570 Filed 8–18–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
[FR Doc. 2010–20614 Filed 8–18–10; 8:45 am]
BILLING CODE 4140–01–P
AGENCY:
17:05 Aug 18, 2010
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
Jkt 220001
PO 00000
Frm 00036
Fmt 4703
Annual hour
burden
100
Expanded Human Immunodeficiency
Virus (HIV) Testing for
Disproportionately Affected
Populations
VerDate Mar<15>2010
Average
time per
response
(in hours)
Frequency of
response
Sfmt 4703
ACTION:
Notice.
Notice of Intent to increase funding
available to make awards under the
Centers for Disease Control and
Prevention Funding Opportunity
Announcement CDC–RFA–PS10–10138,
‘‘Expanded Human Immunodeficiency
Virus (HIV) Testing for
Disproportionately Affected
Populations’’. Additional funding from
the Patient Protection and Affordable
Care Act has been allocated for awards
to state and county and local public
health departments with at least 175
estimated combined AIDS diagnoses
among Blacks/African Americans and
Hispanics/Latinos in 2007.
SUMMARY: This notice provides public
notice of CDC’s intent to increase
available funding for the Centers for
Disease Control and Prevention Funding
Opportunity Announcement PS10–
10138, ‘‘Expanded Human
Immunodeficiency Virus (HIV) Testing
for Disproportionately Affected
Populations’’ to make awards to state
and county and local public health
departments. It is the intent of CDC to
increase the amount of funds available
to applicants who applied for awards
under the previously announced
funding opportunity CDC–RFA–PS10–
10138, which closed on June 24, 2010.
CDC received additional funding
through the Patient Protection
Affordable Care Act (PPACA), Section
4002 Prevention and Public Health
Fund. Accordingly CDC adds the
following information to the previously
published funding opportunity
announcement:
—Catalog of Federal Domestic
Assistance Number: 93.523 The
Affordable Care Act: Human
Immunodeficiency Virus (HIV)
Prevention and Public Health Fund
Activities.
—Authority: This program is authorized
under Sections 301 and 318 of the
Public Health Service Act (42 U.S.C.
Section 241 and 247c), as amended,
and Section 4002 of the Patient
E:\FR\FM\19AUN1.SGM
19AUN1
51274
Federal Register / Vol. 75, No. 160 / Thursday, August 19, 2010 / Notices
Protection and Affordable Care Act
(Pub. L. 111–148).
—Reporting Requirements: Recipients of
the PPACA funds through this
funding opportunity announcement
are required to comply with the
reporting requirements, terms and
conditions set forth in the published
version of the PS10–10138,
‘‘Expanded Human Immunodeficiency
Virus (HIV) Testing for
Disproportionately Affected
Populations’’ (CDC–RFA–PS10–
10138).
—CFDA Number 93.523 The Affordable
Care Act: Human Immunodeficiency
Virus (HIV) Prevention and Public
Health Fund Activities is the PPACAspecific CFDA number for this
initiative. It is included in addition to
the CFDA Number 93.940, HIV
Prevention Activities for Health
Departments, published in the abovereferenced Funding Opportunity
Announcement (FOA).
Award Information:
Type of Award: Cooperative
Agreement.
Fiscal Year Funds: Fiscal Year 2010,
Funding for this announcement will
include a combination of HIV
Prevention funding and funds from the
PPACA, Prevention and Public Health
Fund. Available funding amounts,
including the additional PPHF funds,
are as follows.
Part A—HIV Screening and HIV
Counseling, Testing, and Referral
Approximate Current Fiscal Year
Funding: Up to $60,000,000 total (to
include up to $55,633,000 in Enhanced
HIV Testing funds and adding
$4,367,000 in Patient Protection and
Affordable Care Act of 2010 funds).
Approximate Total Project Period
Funding: $166,899,000. (This amount is
an estimate, and is subject to availability
of funds. This amount includes direct
and indirect costs.)
Approximate Number of Awards: 30.
Approximate Average Award:
$2,000,000. The average awards will be
proportionately based on estimated
combined 2007 Black/African American
and Hispanic/Latino AIDS diagnoses for
eligible jurisdictions. (These amounts
are for the first 12-month budget period,
and include both direct and indirect
costs.)
Floor and Ceiling of Individual Award
Ranges:
Floor of individual award
range
Jurisdiction
Florida ..............................................................................................................................................................
New York City ..................................................................................................................................................
California ..........................................................................................................................................................
Texas ...............................................................................................................................................................
New York State ................................................................................................................................................
Georgia ............................................................................................................................................................
Maryland ..........................................................................................................................................................
North Carolina ..................................................................................................................................................
Louisiana ..........................................................................................................................................................
Puerto Rico ......................................................................................................................................................
Houston ............................................................................................................................................................
District of Columbia .........................................................................................................................................
New Jersey ......................................................................................................................................................
Philadelphia .....................................................................................................................................................
South Carolina .................................................................................................................................................
Chicago ............................................................................................................................................................
Virginia .............................................................................................................................................................
Los Angeles .....................................................................................................................................................
Pennsylvania ....................................................................................................................................................
Michigan ...........................................................................................................................................................
Tennessee .......................................................................................................................................................
Illinois ...............................................................................................................................................................
Ohio .................................................................................................................................................................
Massachusetts .................................................................................................................................................
Alabama ...........................................................................................................................................................
Mississippi ........................................................................................................................................................
Connecticut ......................................................................................................................................................
Missouri ............................................................................................................................................................
Arizona .............................................................................................................................................................
San Francisco ..................................................................................................................................................
$4,307,446
3,998,517
2,482,306
2,094,529
1,861,862
1,788,184
1,700,288
1,303,462
1,302,170
1,258,222
1,197,470
1,140,596
1,059,163
1,042,359
985,485
968,681
852,348
803,229
801,937
798,059
774,792
707,578
684,311
667,507
642,948
605,463
602,878
549,881
542,126
476,204
REVISED Ceiling
of individual
award range*
$6,818,721
6,329,161
3,926,423
3,311,912
2,943,206
2,826,449
2,687,160
2,058,310
2,056,262
1,986,618
1,890,344
1,800,216
1,671,169
1,644,540
1,554,411
1,527,782
1,343,429
1,265,591
1,263,543
1,257,398
1,220,527
1,114,012
1,077,141
1,050,512
1,011,593
952,191
948,093
864,111
851,820
747,353
* These ceilings are for the first 12-month budget period and include direct and indirect costs.
emcdonald on DSK2BSOYB1PROD with NOTICES
Part B—Enhanced Linkage to Medical
Care and Partner Services
Approximate Current Fiscal Year
Funding: $4,000,000.
Approximate Total Project Period
Funding: $12,000,000 (This amount is
an estimate, and is subject to availability
of funds. This amount includes direct
and indirect costs.)
Approximate Number of Awards: Up
to 20.
VerDate Mar<15>2010
17:05 Aug 18, 2010
Jkt 220001
Approximate Average Award:
$200,000 (This amount is for the first
12-month budget period, and includes
both direct and indirect costs.)
Floor of Individual Award Range:
$ 150,000.
Ceiling of Individual Award Range:
$ 225,000 (This ceiling is for the first 12month budget period and includes
direct and indirect costs.)
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Both Part A (HIV Screening and HIV
Counseling, Testing, and Referral) and
Part B (Enhanced Linkage to Medical
Care and Partner Services)
Anticipated Award Date: September
30, 2010.
Budget Period Length: 12 months.
Project Period Length: 3 years
(Availability of PPACA funds beyond
the initial 12 months will be based on
availability of future funding.)
E:\FR\FM\19AUN1.SGM
19AUN1
Federal Register / Vol. 75, No. 160 / Thursday, August 19, 2010 / Notices
Throughout the project period, CDC’s
commitment to continuation of awards
will be conditioned on the availability
of funds, evidence of satisfactory
progress by the recipient (as
documented in required reports), and
the determination that continued
funding is in the best interest of the
Federal government.
Application Selection Process
CDC will apply the same selection
methodology published in the CDC–
RFA–PS10–10138.
Funding Authority
CDC will add the PPACA Authority to
that which is currently reflected in the
published Funding Opportunity CDC–
RFA–PS10–10138. The revised funding
authority language will read:
—This program is authorized under
Sections 301 and 318 of the Public
Health Service Act (42 U.S.C. Section
241 and 247c), as amended, and
Section 4002 of the Patient Protection
and Affordable Care Act (Pub. L. 111–
148).
DATES: The effective date for this action
is August 19, 2010 and remains in effect
until the expiration of the project period
of the PPACA funded applications.
FOR FURTHER INFORMATION CONTACT:
Elmira Benson, Acting Deputy Director,
Centers for Disease Control and
Prevention, 2920 Brandywine Road,
Atlanta, GA 30341, telephone (770)
488–2802, e-mail:
Elmira.Benson@cdc.gov.
On March
23, 2010, the President signed into law
the Patient Protection and Affordable
Care Act (PPACA), Public Law 111–148.
PPACA is designed to improve and
expand the scope of health care
coverage for Americans. Cost savings
through disease prevention is an
important element of this legislation
and PPACA has established a
Prevention and Public Health Fund
(PPHF) for this purpose. Specifically,
the legislation states in Section 4002
that the PPHF is to ‘‘provide for
expanded and sustained national
investment in prevention and public
health programs to improve health and
help restrain the rate of growth in
private and public sector health care
costs.’’ PPACA and the Prevention and
Public Health Fund make improving
public health a priority with
investments to improve public health.
The PPHF states that the Secretary
shall transfer amounts in the Fund to
accounts within the Department of
Health and Human Services to increase
funding, over the fiscal year 2008 level,
for programs authorized by the Public
emcdonald on DSK2BSOYB1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
17:05 Aug 18, 2010
Jkt 220001
Health Service Act, for prevention,
wellness and public health activities
including prevention research and
health screenings, such as the
Community Transformation Grant
Program, the Education and Outreach
Campaign for Preventative Benefits, and
Immunization Programs.
PPACA legislation affords an
important opportunity to advance
public health across the lifespan and to
reduce health disparities by supporting
an intensive community approach to
chronic disease prevention and control.
Therefore, increasing funding
available to applicants under this FOA
using the PPHF to further HIV
prevention programs is consistent with
the purpose of the PPHF, as stated
above, to provide for an expanded and
sustained national investment in
prevention and public health programs.
Further, the Secretary allocated funds to
CDC, pursuant to the PPHF, for the
types of activities this FOA is designed
to carry out.
Dated: August 13, 2010.
Tanja Popovic, MD, PhD, F(AMM),
AM(AAFS),
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
51275
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Dental and Craniofacial Research Council.
Date: September 27, 2010.
Open: 8:30 a.m. to 12:30 p.m.
Agenda: Report of the Director, NIDCR.
Place: National Institutes of Health,
Building 31C, 31 Center Drive, 6th Floor, 10,
Bethesda, MD 20892.
Closed: 1:30 p.m. to Adjournment.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31C, 31 Center Drive, 6th Floor, 10,
Bethesda, MD 20892.
Contact Person: Alicia J. Dombroski, PhD,
Director, Division of Extramural Activities,
National Institute of Dental and Craniofacial
Research, National Institutes of Health,
Bethesda, MD 20892.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
[FR Doc. 2010–20572 Filed 8–18–10; 8:45 am]
Dated: August 13, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
BILLING CODE P
[FR Doc. 2010–20610 Filed 8–18–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Dental and
Craniofacial Research; Notice of
Meeting
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Dental and
Craniofacial Research Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Subcommittee for Planning the Annual
Strategic Plan Updating Process of the
Interagency Autism Coordinating
Committee (IACC). The Subcommittee
meeting will be conducted as a
telephone conference call and webinar.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
National Institute of Mental Health;
Notice of Meeting
Name of Committee: Interagency Autism
Coordinating Committee (IACC).
Type of Meeting: Subcommittee for
Planning the Annual Strategic Plan Updating
Process.
Date: September 21, 2010.
Time: 1 p.m. to 3 p.m. Eastern Time.
Agenda: To discuss plans for updating the
IACC Strategic Plan for ASD Research.
Place: No in-person meeting; conference
call and webinar only.
Webinar Access: https://www2.
gotomeeting.com/register/461944091.
Registration: No pre-registration required.
Conference Call: Dial: 800–369–3340.
Access code: 8415008.
E:\FR\FM\19AUN1.SGM
19AUN1
]]>Agencies
[Federal Register Volume 75, Number 160 (Thursday, August 19, 2010)]
[Notices]
[Pages 51273-51275]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-20572]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention (CDC)
Expanded Human Immunodeficiency Virus (HIV) Testing for
Disproportionately Affected Populations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
Notice of Intent to increase funding available to make awards under
the Centers for Disease Control and Prevention Funding Opportunity
Announcement CDC-RFA-PS10-10138, ``Expanded Human Immunodeficiency
Virus (HIV) Testing for Disproportionately Affected Populations''.
Additional funding from the Patient Protection and Affordable Care Act
has been allocated for awards to state and county and local public
health departments with at least 175 estimated combined AIDS diagnoses
among Blacks/African Americans and Hispanics/Latinos in 2007.
SUMMARY: This notice provides public notice of CDC's intent to increase
available funding for the Centers for Disease Control and Prevention
Funding Opportunity Announcement PS10-10138, ``Expanded Human
Immunodeficiency Virus (HIV) Testing for Disproportionately Affected
Populations'' to make awards to state and county and local public
health departments. It is the intent of CDC to increase the amount of
funds available to applicants who applied for awards under the
previously announced funding opportunity CDC-RFA-PS10-10138, which
closed on June 24, 2010.
CDC received additional funding through the Patient Protection
Affordable Care Act (PPACA), Section 4002 Prevention and Public Health
Fund. Accordingly CDC adds the following information to the previously
published funding opportunity announcement:
--Catalog of Federal Domestic Assistance Number: 93.523 The Affordable
Care Act: Human Immunodeficiency Virus (HIV) Prevention and Public
Health Fund Activities.
--Authority: This program is authorized under Sections 301 and 318 of
the Public Health Service Act (42 U.S.C. Section 241 and 247c), as
amended, and Section 4002 of the Patient
[[Page 51274]]
Protection and Affordable Care Act (Pub. L. 111-148).
--Reporting Requirements: Recipients of the PPACA funds through this
funding opportunity announcement are required to comply with the
reporting requirements, terms and conditions set forth in the published
version of the PS10-10138, ``Expanded Human Immunodeficiency Virus
(HIV) Testing for Disproportionately Affected Populations'' (CDC-RFA-
PS10-10138).
--CFDA Number 93.523 The Affordable Care Act: Human Immunodeficiency
Virus (HIV) Prevention and Public Health Fund Activities is the PPACA-
specific CFDA number for this initiative. It is included in addition to
the CFDA Number 93.940, HIV Prevention Activities for Health
Departments, published in the above-referenced Funding Opportunity
Announcement (FOA).
Award Information:
Type of Award: Cooperative Agreement.
Fiscal Year Funds: Fiscal Year 2010, Funding for this announcement
will include a combination of HIV Prevention funding and funds from the
PPACA, Prevention and Public Health Fund. Available funding amounts,
including the additional PPHF funds, are as follows.
Part A--HIV Screening and HIV Counseling, Testing, and Referral
Approximate Current Fiscal Year Funding: Up to $60,000,000 total
(to include up to $55,633,000 in Enhanced HIV Testing funds and adding
$4,367,000 in Patient Protection and Affordable Care Act of 2010
funds).
Approximate Total Project Period Funding: $166,899,000. (This
amount is an estimate, and is subject to availability of funds. This
amount includes direct and indirect costs.)
Approximate Number of Awards: 30.
Approximate Average Award: $2,000,000. The average awards will be
proportionately based on estimated combined 2007 Black/African American
and Hispanic/Latino AIDS diagnoses for eligible jurisdictions. (These
amounts are for the first 12-month budget period, and include both
direct and indirect costs.)
Floor and Ceiling of Individual Award Ranges:
------------------------------------------------------------------------
Floor of REVISED Ceiling
Jurisdiction individual award of individual
range award range*
------------------------------------------------------------------------
Florida............................. $4,307,446 $6,818,721
New York City....................... 3,998,517 6,329,161
California.......................... 2,482,306 3,926,423
Texas............................... 2,094,529 3,311,912
New York State...................... 1,861,862 2,943,206
Georgia............................. 1,788,184 2,826,449
Maryland............................ 1,700,288 2,687,160
North Carolina...................... 1,303,462 2,058,310
Louisiana........................... 1,302,170 2,056,262
Puerto Rico......................... 1,258,222 1,986,618
Houston............................. 1,197,470 1,890,344
District of Columbia................ 1,140,596 1,800,216
New Jersey.......................... 1,059,163 1,671,169
Philadelphia........................ 1,042,359 1,644,540
South Carolina...................... 985,485 1,554,411
Chicago............................. 968,681 1,527,782
Virginia............................ 852,348 1,343,429
Los Angeles......................... 803,229 1,265,591
Pennsylvania........................ 801,937 1,263,543
Michigan............................ 798,059 1,257,398
Tennessee........................... 774,792 1,220,527
Illinois............................ 707,578 1,114,012
Ohio................................ 684,311 1,077,141
Massachusetts....................... 667,507 1,050,512
Alabama............................. 642,948 1,011,593
Mississippi......................... 605,463 952,191
Connecticut......................... 602,878 948,093
Missouri............................ 549,881 864,111
Arizona............................. 542,126 851,820
San Francisco....................... 476,204 747,353
------------------------------------------------------------------------
* These ceilings are for the first 12-month budget period and include
direct and indirect costs.
Part B--Enhanced Linkage to Medical Care and Partner Services
Approximate Current Fiscal Year Funding: $4,000,000.
Approximate Total Project Period Funding: $12,000,000 (This amount
is an estimate, and is subject to availability of funds. This amount
includes direct and indirect costs.)
Approximate Number of Awards: Up to 20.
Approximate Average Award: $200,000 (This amount is for the first
12-month budget period, and includes both direct and indirect costs.)
Floor of Individual Award Range: $ 150,000.
Ceiling of Individual Award Range: $ 225,000 (This ceiling is for
the first 12-month budget period and includes direct and indirect
costs.)
Both Part A (HIV Screening and HIV Counseling, Testing, and Referral)
and Part B (Enhanced Linkage to Medical Care and Partner Services)
Anticipated Award Date: September 30, 2010.
Budget Period Length: 12 months.
Project Period Length: 3 years (Availability of PPACA funds beyond
the initial 12 months will be based on availability of future funding.)
[[Page 51275]]
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal government.
Application Selection Process
CDC will apply the same selection methodology published in the CDC-
RFA-PS10-10138.
Funding Authority
CDC will add the PPACA Authority to that which is currently
reflected in the published Funding Opportunity CDC-RFA-PS10-10138. The
revised funding authority language will read:
--This program is authorized under Sections 301 and 318 of the Public
Health Service Act (42 U.S.C. Section 241 and 247c), as amended, and
Section 4002 of the Patient Protection and Affordable Care Act (Pub. L.
111-148).
DATES: The effective date for this action is August 19, 2010 and
remains in effect until the expiration of the project period of the
PPACA funded applications.
FOR FURTHER INFORMATION CONTACT: Elmira Benson, Acting Deputy Director,
Centers for Disease Control and Prevention, 2920 Brandywine Road,
Atlanta, GA 30341, telephone (770) 488-2802, e-mail:
Elmira.Benson@cdc.gov.
SUPPLEMENTARY INFORMATION: On March 23, 2010, the President signed into
law the Patient Protection and Affordable Care Act (PPACA), Public Law
111-148. PPACA is designed to improve and expand the scope of health
care coverage for Americans. Cost savings through disease prevention is
an important element of this legislation and PPACA has established a
Prevention and Public Health Fund (PPHF) for this purpose.
Specifically, the legislation states in Section 4002 that the PPHF is
to ``provide for expanded and sustained national investment in
prevention and public health programs to improve health and help
restrain the rate of growth in private and public sector health care
costs.'' PPACA and the Prevention and Public Health Fund make improving
public health a priority with investments to improve public health.
The PPHF states that the Secretary shall transfer amounts in the
Fund to accounts within the Department of Health and Human Services to
increase funding, over the fiscal year 2008 level, for programs
authorized by the Public Health Service Act, for prevention, wellness
and public health activities including prevention research and health
screenings, such as the Community Transformation Grant Program, the
Education and Outreach Campaign for Preventative Benefits, and
Immunization Programs.
PPACA legislation affords an important opportunity to advance
public health across the lifespan and to reduce health disparities by
supporting an intensive community approach to chronic disease
prevention and control.
Therefore, increasing funding available to applicants under this
FOA using the PPHF to further HIV prevention programs is consistent
with the purpose of the PPHF, as stated above, to provide for an
expanded and sustained national investment in prevention and public
health programs. Further, the Secretary allocated funds to CDC,
pursuant to the PPHF, for the types of activities this FOA is designed
to carry out.
Dated: August 13, 2010.
Tanja Popovic, MD, PhD, F(AMM), AM(AAFS),
Deputy Associate Director for Science, Centers for Disease Control and
Prevention.
[FR Doc. 2010-20572 Filed 8-18-10; 8:45 am]
BILLING CODE P
